180 Life Sciences Corp. Files Q2 2024 10-Q Report
Ticker: FRMM · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1690080
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
180 Life Sciences filed its Q2 10-Q. All good.
AI Summary
180 Life Sciences Corp. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, formerly known as KBL Merger Corp. IV, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Palo Alto, California.
Why It Matters
This filing provides investors with an update on the financial performance and operational status of 180 Life Sciences Corp. during the second quarter of 2024.
Risk Assessment
Risk Level: low — This is a standard quarterly filing providing basic company information and no immediate red flags.
Key Numbers
- 001-38105 — SEC File Number (Identifies the company's filing history with the SEC.)
- 1231 — Fiscal Year End (Indicates the end of the company's annual accounting period.)
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL Merger Corp. IV (company) — Former company name
- June 30, 2024 (date) — Quarterly period end date
- August 12, 2024 (date) — Filing date
- 2834 (other) — Standard Industrial Classification code for Pharmaceutical Preparations
FAQ
What is the primary business of 180 Life Sciences Corp.?
180 Life Sciences Corp. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.
When was the company's name changed?
The company's name was changed from KBL Merger Corp. IV on November 15, 2016.
What is the filing date of this 10-Q report?
This 10-Q report was filed on August 12, 2024.
Where are 180 Life Sciences Corp.'s principal executive offices located?
The principal executive offices are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.
What is the SEC file number for 180 Life Sciences Corp.?
The SEC file number for 180 Life Sciences Corp. is 001-38105.
Filing Stats: 4,583 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-08-12 17:00:21
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Market
Filing Documents
- ea0210822-10q_180life.htm (10-Q) — 729KB
- ea021082201ex31-1_180life.htm (EX-31.1) — 10KB
- ea021082201ex31-2_180life.htm (EX-31.2) — 10KB
- ea021082201ex32-1_180life.htm (EX-32.1) — 3KB
- ea021082201ex32-2_180life.htm (EX-32.2) — 3KB
- image_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-067741.txt ( ) — 4589KB
- atnf-20240630.xsd (EX-101.SCH) — 49KB
- atnf-20240630_cal.xml (EX-101.CAL) — 32KB
- atnf-20240630_def.xml (EX-101.DEF) — 228KB
- atnf-20240630_lab.xml (EX-101.LAB) — 422KB
- atnf-20240630_pre.xml (EX-101.PRE) — 232KB
- ea0210822-10q_180life_htm.xml (XML) — 475KB
Financial Statements
Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three and Six Months Ended June 30, 2024 and 2023 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 ITEM 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 ITEM 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 34 ITEM 4.
Controls and Procedures
Controls and Procedures 34 PART II 36 OTHER INFORMATION ITEM 1. Legal Proceedings. 36 ITEM 1A. Risk Factors. 36 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds. 38 ITEM 3. Defaults Upon Senior Securities. 38 ITEM 4. Mine Safety Disclosures. 38 ITEM 5. Other Information. 38 ITEM 6. Exhibits. 39
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION
Financial
Item 1. Financial 180 LIFE SCIENCES CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2024 2023 (Unaudited) Current Assets: Cash $ 1,146,288 $ 1,975,799 Prepaid expenses and other current assets 1,201,202 1,664,107 Total Current Assets 2,347,490 3,639,906 Intangible assets, net 1,563,955 1,619,570 Total Assets $ 3,911,445 $ 5,259,476 Liabilities and Stockholders' Deficit Current Liabilities: Accounts payable $ 2,555,238 $ 1,892,611 Accounts payable - related parties 364,645 266,009 Accrued expenses 559,733 1,869,814 Accrued expenses - related parties 107,515 - Loans payable - current portion 428,996 1,034,124 Derivative liabilities - 58 Total Current Liabilities 4,016,127 5,062,616 Accrued issuable equity - - Loans payable - noncurrent portion 13,289 19,936 Deferred tax liability 300,016 304,657 Total Liabilities 4,329,432 5,387,209 Commitments and contingencies (Note 8) Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 5,000,000 shares authorized; (see designations and shares authorized for Series A, Class C and Class K preferred stock) Class C Preferred Stock; 1 share authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively - - Class K Preferred Stock; 1 share authorized, 1 and 0 shares issued and outstanding, at June 30, 2024 and December 31, 2023, respectively - - Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 941,590 and 534,719 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 95 54 Additional paid-in capital 130,899,278 130,117,209 Accumulated other comprehensive income ( 2,915,740 ) ( 2,901,339 ) Accumulated deficit ( 128,401,620 ) ( 127,343,657 ) Total Stockholders' Deficit ( 417,987 ) ( 127,733 ) Total Liabilities and Stockholders' Deficit $ 3,911,445 $ 5,259,476 The accompanying notes are an inte